1-4 of 4
Jonathan A. Cooper
Close
Sort by
Journal Articles

Tyrosine Phosphorylation Enhances ITIM-Dependent Internalization of CD33, the Target for the Anti-AML Immunoconjugate, Gemtuzumab Ozogamicin.

Roland B. Walter, MD, Brian W. Raden, BS, Irwin D. Bernstein, MD, Jonathan A. Cooper, PhD
Journal: Blood
Blood (2006) 108 (11): 2581.
https://doi.org/10.1182/blood.V108.11.2581.2581
Published: 2006
Journal Articles

Lysosomal Degradation of CD33, the Target for the Anti-Leukemia Immunoconjugate, Gemtuzumab Ozogamicin: Evidence for Cbl-Mediated Monoubiquitination.

Roland B. Walter, MD, Brian W. Raden, BS, Darren M. Kamikura, PhD, Irwin D. Bernstein, MD, Jonathan A. Cooper, PhD
Journal: Blood
Blood (2005) 106 (11): 2469.
https://doi.org/10.1182/blood.V106.11.2469.2469
Published: 2005
Journal Articles

Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin–induced cytotoxicity

Roland B. Walter, Brian W. Raden, Darren M. Kamikura, Jonathan A. Cooper, Irwin D. Bernstein
Journal: Blood
Blood (2005) 105 (3): 1295–1302.
https://doi.org/10.1182/blood-2004-07-2784
Published: 2005
Journal Articles

Influence of CD33 Expression Levels and ITIM-Dependent Internalization on Gemtuzumab Ozogamicin-Induced Cytotoxicity.

Roland B. Walter, MD, Brian W. Raden, MS, Darren M. Kamikura, PhD, Jonathan A. Cooper, PhD, Irwin D. Bernstein, MD
Journal: Blood
Blood (2004) 104 (11): 1176.
https://doi.org/10.1182/blood.V104.11.1176.1176
Published: 2004